The use of fatty acid beta-oxidation inhibitor mildronate as monotherapy or in combination with atenolol in patients with left ventricular dysfunction after myocardial infarction;Miokardial'naia tsitoprotektsiia ingibitorom beta-okisleniia zhirnykh kislot mildronatom v vide monoterapii i v sochetanii s beta-adrenoblokatorom atenololom u bol'nykh s postinfarktnoi disfunktsiei levogo zheludochka.

Kardiologiia

Volumn 43, Issue 12, 2003, Pages 15-18

  Teplyakov, A T ^a   Sankevitch, T V ^a   Stepatcheva, T A ^a   Mamchur, S E ^a  

^a CARDIOLOGY RESEARCH INSTITUTE   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2,2,2 TRIMETHYLHYDRAZINE)PROPIONATE; 3-(2,2,2-TRIMETHYLHYDRAZINE)PROPIONATE; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; FATTY ACID BETA OXIDATION MULTIENZYME COMPLEX; FATTY ACID BETA-OXIDATION MULTIENZYME COMPLEX; METHYLHYDRAZINE DERIVATIVE; MULTIENZYME COMPLEX;

ARTICLE; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG COMBINATION; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; MALE; MIDDLE AGED;

ADRENERGIC BETA-ANTAGONISTS; ATENOLOL; CARDIOVASCULAR AGENTS; DRUG THERAPY, COMBINATION; HUMANS; MALE; METHYLHYDRAZINES; MIDDLE AGED; MULTIENZYME COMPLEXES; MYOCARDIAL INFARCTION; VENTRICULAR DYSFUNCTION, LEFT;

EID: 3042700210     PISSN: 00229040     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)